The effects of prior calcium channel blocker therapy on creatine kinase-MB levels after percutaneous coronary interventions

Vascular Health and Risk Management

Volumn 4, Issue 6, 2008, Pages 1417-1422

  Gulmez, Oyku ^a,b   Atar, Ilyas ^a   Ozin, Bülent ^a   Korkmaz, Mehmet Emin ^a   Atar, Asli ^a   Aydinalp, Alp ^a   Yildirir, Aylin ^a   Muderrisoglu, Haldun ^a  

^a BASKENT UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Calcium channel blockers; Myonecrosis; Percutaneous coronary interventions

Indexed keywords

AMLODIPINE; CALCIUM CHANNEL BLOCKING AGENT; CREATINE KINASE MB; DILTIAZEM; FELODIPINE; VERAPAMIL;

ADULT; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY SPASM; DRUG EFFICACY; ENZYME BLOOD LEVEL; FEMALE; HEART INFARCTION; HEART MUSCLE NECROSIS; HUMAN; INTRAOPERATIVE PERIOD; MAJOR CLINICAL STUDY; MALE; OPERATION DURATION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PEROPERATIVE CARE;

ADMINISTRATION, ORAL; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BIOLOGICAL MARKERS; CALCIUM CHANNEL BLOCKERS; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; CREATINE KINASE, MB FORM; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIUM; NECROSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 60249097644     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Abdelmeguid AE, Topol EJ, Whitlow PL, et al. 1996. Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronaty interventions. Circulation, 94:1528-36.
2. Abdelmeguid AE, Topol EJ. 1996. The myth of the myocardial 'infarctlet' during percutaneous coronary revascularization procedures. Circulation, 94:3369-75.
3. Akkerhuis KM, Alexander JH, Tardiff BE, et al. 2002. Minor myocardial damage and prognosis. Circulation, 105:554-6.
4. Aronow HD, McRae T, Quinn MJ. 2002b. Patients on lipid-lowering therapy at the time of myocardial infarction have smaller infarcts: further evidence to suggest a salutary effect in acute coronary syndrome [abstract]. J Am Coll Cardiol, 39:318A.
5. Aronow HD, Quinn MJ, Gurm HS. 2002a. Myocardial necrosis is halved in patients undergoing elective percutaneous coronary intervention who are pretreated with lipid-lowering therapy [abstract]. J Am Coll Cardiol, 39:32A.
6. Bestehorn HP, Neumann FJ, Büttner HJ, et al. 2004. Evaluation of the oral verapamil on clinical outcome and angiographic restenosis after percutaneous coronary intervention. The randomized, double-blind, placebo-controlled, multicenter verapamil slow-release for prevention of cardiovascular events after angioplasty (VESPA) trial. J Am Coll Cardiol, 43:2160-5.
7. Califf RM, Abdelmeguid AE, Kuntz RE, et al. 1998. Myonecrosis after revascularization procedures. J Am Coll Cardiol, 31:241-51.
8. Demir I, Yilmaz H, Ermiş C, et al. 2002. Treatment of no re-flow phenomenon with verapamil after primary stent deployment during myocardial infarction. Jpn Heart J, 43:573-80.
9. Dens J, Desmet W, Piessens J. 2003. An updated meta-analysis of calcium-channel blockers in the prevention of restenosis after coronary angioplasty. Am Heart J, 145:404-8.
10. Desmet WJ, Dens J, Coussement P, et al. 2002. Does adenosine prevent myocardial micronecrosis following percutaneous coronary intervention? The ADELINE pilot trial. ADEnosine Limit myocardial Necrosis. Heart, 88:293-5.
11. Ellis S, Sorin JB, Lincoff AM, et al. 2001. Beta-blockers before percutaneous coronary intervention do not attenuate postprocedural creatine kinase isoenzyme rise. Circulation, 104:2685-8.
12. [ENCORE] The ENCORE Investigators. 2003. Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: the ENCORE I Study (Evaluation of Nifedipine and Cerivastatin in Recovery of coronary Endothelial function). Circulation, 107:422-8.
13. [EPISTENT] The EPISTENT Investigators. 1998. Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet, 352:87-92.
14. Folts JD. 1997. Inhibition of platelet activity in vivo by amlodipine alone and combined with aspirin. Int J Cardiol, 62: S111-7.
15. Herrmann J, Lerman A, Baumgart D, et al. 2002. Preprocedural statin medication reduces the extent of per procedural non-Q-wave myocardial infarction. Circulation, 106:2180-3.
16. Klein HH, Pich S, Lindert S, et al. 1989. Comparative study on the enchanment of ischemic tolerance by intracoronary pretreatment with three calcium antagonists in pig hearts. Cardiovasc Drugs Ther, 2:815-21.
17. Kurz DJ, Naegeli B, Bertel O. 2000. A double-blind, randomized study of the effect of immediate intravenous nitroglycerin on the incidence of postprocedural chest pain and minor myocardial necrosis after elective coronary stenting. Am Heart J, 139:35-43.
18. Matthews MA, Kunselman SJ, Gascho JA, et al. 2005. Differential release of cardiac enzymes after percutaneous coronary intervention. Catheter Cardiovasc Interv, 65:19-24.
19. Michaels AD, Appleby M, Otten MH, et al. 2002. Pretreatment with intragraft verapamil prior to PCI of saphenous vein graft lesions: results of the randomised controlled vasodilator prevention on no-reflow (VAPOR) trial. J Invasive Cardiol, 14:299-302.
20. Pasceri V, Patti G, Nusca A, et al; ARMYDA Investigators. 2004. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation, 110:674-8.
21. Roberts R, Rogers WJ, Mueller HS, et al. 1991. Immediate versus deferred B-blockage following thrombolytic therapy in patients with acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) II-B study. Circulation, 83:422-37.
22. Sato M, Harding SE, Poole-Wilson PA. 2004. B-blockers, myocardial ischemia and collateral circulation. Eur Heart J, 25:537-9.
23. Sharma SK, Kini A, Marmur JD, et al. 2000. Cardioprotective effect of prior B-blocker therapy in reducing creatine- kinase-MB elevation after coronary intervention: benefit is extended to improvement in intermediate-term survival. Circulation, 102:166-72.
24. Simoons ML, van den Brand M, Lincoff M, et al. 1999. Minimal myocardial damage during coronary intervention is associated with impaired outcome. Eur Heart J, 20:1112-9.
25. Taddei S, Virdis A, Ghiadoni L, et al. 2001. Restoration of nitric oxide availability after calcium antagonist treatment in essential hypertension. Hypertension, 37:943-8.
26. Tardiff BE, Califf RM, Tcheng JE, et al. 1999. Clinical outcomes after detection of elevated cardiac enyzmes in patients undergoing percutaneous intervention. IMPACT II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II. J Am Coll Cardiol, 33:88-96.
27. Voisard R, Koschnick S, Baur R, et al. 1997. High-dose diltiazem prevents migration and proliferation of vascular smooth muscle cells in various in-vitro models of human coronary restenosis. Coron Artery Dis, 8:189-201.
28. Wang FW, Osman A, Otero J, et al. 2003. Distal myocardial protection during percutaneous coronary intervention with an intracoronary beta-blocker. Circulation, 107:2914-9.
29. Werner GS, Lang K, Kuehnert H, et al. 2002. Intracoronary verapamil for reversal of no-reflow during coronary angioplasty for acute myocardial infarction. Cathet Cardiovasc Interv, 57:444-51.
30. Yang Z, Noll G, Luscher TF. 1993. Calcium channel antagonists differently inhibit proliferation of human coronary smooth muscle cells in response to pulsatile stretch and platelet derived growth factor. Circulation, 88:832-6.